Beyond The Numbers: 6 Analysts Discuss ResMed Stock
Beyond The Numbers: 6 Analysts Discuss ResMed Stock
數字背後：6位分析師討論瑞思邁股票
Analysts' ratings for ResMed (NYSE:RMD) over the last quarter vary from bullish to bearish, as provided by 6 analysts.
過去一個季度瑞思邁（NYSE：RMD）的分析師評級從看好到看淡不等，由6位分析師提供。
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
下表提供了分析師最近的評級概述，爲了全面了解過去30天的情緒變化並與前幾個月進行比較，提供了深入的見解。
Analysts have set 12-month price targets for ResMed, revealing an average target of $222.33, a high estimate of $238.00, and a low estimate of $200.00. Surpassing the previous average price target of $215.67, the current average has increased by 3.09%.
分析師爲瑞思邁設定了12個月的價格目標，透露出平均目標爲222.33美元，最高預估爲238.00美元，最低預估爲200.00美元。當前的平均目標超過了215.67美元的上一個平均目標，平均漲幅爲3.09%。
Deciphering Analyst Ratings: An In-Depth Analysis
分析師評級解讀：深入分析
The analysis of recent analyst actions...
最近分析師行...
登入免費觀看全文
登入/註冊
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。